Accrufer Approved to Treat Iron Deficiency
July 25, 2019 – The U.S. FDA has approved Accrufer™ (ferric maltol), manufactured by Shield Therapeutics, to treat iron deficiency in adults. The product is a new means of treating iron deficiency compared to other products available on the U.S. market.
Current oral treatments for iron deficiency use iron salts that release iron inside of the gastrointestinal (GI) tract. This can cause unpleasant side effects such as nausea and constipation. Intravenous (IV) iron infusions, an alternative to oral treatments, must be administered in a healthcare setting.
A non-salt form of iron, Accrufer reduces the risk of GI upset. Recommended dosing is one 30mg capsule taken twice a day at least one hour before or two hours after consuming food. Treatment should continue until iron levels in the blood reach normal ranges.
Shield Therapeutics has not announced launch or pricing plans.